SGLT2 is improve HF and CKD outcomes, regardless of diabetes status - GLP-1RAs support weight loss and improve ASCVD and liver disease outcomes - Tirzepatide shows superior results in weight reduction (>20%), diabetes prevention, and MASLD improvement. Here, SLC5A2 is linked to chronic kidney disease.